5.
吉非替尼组和厄洛替尼组不良反应
Adverse effects in gefitinib-treated and erlotinib-treated patients
| Adverse effect | Gefitinib group (n=30) | Erlotinib group (n=31) | P |
| Rash | 11 (36.67%) | 20 (64.51%) | 0.030, 1 |
| Diarrhea | 7 (23.33%) | 7 (22.58%) | 0.944, 3 |
| Asthenia | 5 (16.67%) | 4 (12.90%) | 0.679, 2 |
| Anorexia | 5 (16.67%) | 5 (16.13%) | 0.955, 3 |
| Dry skin | 4 (13.33%) | 4 (12.90%) | 0.969, 0 |
| Nausea/vomiting | 3 (10.00%) | 4 (12.90%) | 0.722, 4 |
| Hand-foot syndrome | 3 (10.00%) | 3 (9.67%) | 0.966, 0 |
| Stomatitis | 3 (10.00%) | 2 (6.45%) | 0.785, 2 |